IGF‑1 and VEGF can be used as prognostic indicators for patients with uterine fibroids treated with uterine artery embolization

Mu,Yongxu; He,Junfeng; Yan,Ruiqiang; Hu,Xiaoyan; Liu,Haiyan; Hao,Zhiming

doi:10.3892/etm.2015.2924

IGF‑1 and VEGF can be used as prognostic indicators for patients with uterine fibroids treated with uterine artery embolization

Authors:
- Yongxu Mu
- Junfeng He
- Ruiqiang Yan
- Xiaoyan Hu
- Haiyan Liu
- Zhiming Hao
View Affiliations

Affiliations: Department of Rheumatism, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710049, P.R. China, Department of Intervention, The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia Autonomous Region 014010, P.R. China
Published online on: December 8, 2015 https://doi.org/10.3892/etm.2015.2924
Pages: 645-649

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the association between serum vascular endothelial growth factor (VEGF) and insulin‑like growth factor 1 (IGF‑1) levels and the prognosis of patients with uterine fibroids following uterine artery embolization (UAE) treatment. A total of 70 patients with uterine fibroids and 20 healthy controls were enrolled in this study between 2012 and 2014. The serum levels of IGF‑1 and VEGF were measured using ELISA. Multiple‑factor analysis was performed to assess the association between serum levels of IGF‑1/VEGF and certain clinical characteristics, including size, location, number of uterine fibroids and adenomyosis. Progression‑free survival curves were analyzed using the Kaplan‑Meier method. The serum levels of IGF‑1 and VEGF in patients with uterine fibroids prior to UAE treatment were significantly higher than those in controls (P<0.05). At 1 week after UAE treatment, the serum levels of IGF‑1 and VEGF were significantly lower compared with those prior to UAE treatment. The serum levels of IGF‑1 and VEGF at 1 or 3 months after UAE treatment were significantly higher than those at 1 week after UAE treatment. The serum levels of IGF‑1 and VEGF were significantly correlated with the clinical characteristics of uterine fibroids (P<0.05). Lower levels of IGF‑1 and VEGF in the serum following UAE treatment were associated with an enhanced progression‑free survival of patients. In conclusion, the levels of IGF‑1 and VEGF in the serum following UAE treatment can be used as indicators of prognosis in patients with uterine fibroids.

View Figures

View References

1	Okogbo FO, Ezechi OC, Loto OM and Ezeobi PM: Uterine Leiomyomata in South Western Nigeria, A clinical study of presentations and management outcome. Afr Health Sci. 11:271–278. 2011.PubMed/NCBI
2	Zhang Y, Sun L, Guo Y, Cheng J, Wang Y, Fan S and Duan H: The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids, A meta-analysis. Obstet Gynecol Surv. 69:100–108. 2014. View Article : Google Scholar : PubMed/NCBI
3	Wang A and Yin S: Controversy and challenge in the treatment methods of uterine fibroids. Zhong Guo Quan Ke Yi Xue. 12:14–15. 2009.(In Chinese).
4	Singh C, Gupta M, Tripathi R and Tyagi S: Successful use of transcatheter embolisation in an emergent life-threatening situation of bleeding from uterine arteriovenous malformation. BMJ Case Rep. 2013:2013.
5	Mathonnet M, Descottes B, Valleix D, Labrousse F, Truffinet V and Denizot Y: Quantitative analysis using ELISA of vascular endothelial growth factor and basic fibroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and hepatocellular carcinoma. World J Gastroenterol. 12:3782–3783. 2006.PubMed/NCBI
6	Fan ZR, Yang DH, Zuo HR, Xu Z and Qiu QL: Expressions of IGF-I, IGF-II and their receptor mRNAs in hepatocellular carcinomas and adjacent non-tumor tissues. Ai Zheng. 19150–152. (155)2000.(In Chinese).
7	Pourgholami MH and Morris DL: Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem. 6:343–347. 2008. View Article : Google Scholar : PubMed/NCBI
8	Dai B, Wang DS, Zhang Y, Zhou L, Liu J and Sun W: The role of insulin-like growth factors in tumor. Zhong Hua Lin Chuang Yi Shi Za Zhi (Dian Zi Ban). 7:7099–7102. 2013.(In Chinese).
9	Ding ZX, Zhang LZ and Ling L: Levels of matrix metalloproteinase and vascular endothelial growth factor in patients with primary liver cancer. Gan Zang. 10:214–215. 2005.(In Chinese).
10	Liao D, Fan Z and Huang R: Clinical Report of treating uterine fibroids and uterine adenomyosis with uterine artery embolization. Wei Chuang Yi Xue. 7:256–258. 2012.(In Chinese).
11	Gu J, Guan Q, Ji W and Ren W: The influence of serum HIF-1a and VEGF content on the prognosis in patients with hepatocellular carcinoma after TACE. Jie Ru Fang She Xue Za Zhi. 23:142–146. 2014.(In Chinese).
12	Marina O, Suh JH, Reddy CA, Barnett GH, Vogelbaum MA, Peereboom DM, Stevens GH, Elinzano H and Chao ST: Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. Histopathology. J Neurosurg. 115:220–229. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ahmad A, Qadan L, Hassan N and Najarian K: Uterine artery embolization treatment of uterine fibroids, effect on ovarian function in younger women. J Vasc Interv Radiol. 13:1017–1020. 2002. View Article : Google Scholar : PubMed/NCBI
14	Pelage JP, Cazejust J, Pluot E, Le Dref O, Laurent A, Spies JB, Chagnon S and Lacombe P: Uterine fibroid vascularization and clinical relevance to uterine fibroid embolization. Radiographics. 25((Suppl 1)): S99–S117. 2005. View Article : Google Scholar : PubMed/NCBI
15	Wang L: Clinical study of treating uterine fibroids with uterine artery embolization. Zhong Guo Yi Yao. 2:238–241. 2012.(In Chinese).
16	Qu W, Guo P and Wu Y: Clinical research of uterine artery embolization for symptomatic hysteromyoma. J Pract Med Tech. 18:573–576. 2011.
17	Ji W, Xin X and Chen B: The influence of insulin-like growth factor 1 and insulin-like growth factor 1 receptor on the growth of uterine leiomyoma. Zhong Guo Zhong Liu Lin Chuang Yu Kang Fu. 10:24–26. 2003.(In Chinese).